TWI636782B - （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥 - Google Patents

（＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥 Download PDF

Info

Publication number
TWI636782B
TWI636782B TW103119743A TW103119743A TWI636782B TW I636782 B TWI636782 B TW I636782B TW 103119743 A TW103119743 A TW 103119743A TW 103119743 A TW103119743 A TW 103119743A TW I636782 B TWI636782 B TW I636782B
Authority
TW
Taiwan
Prior art keywords
methyl
oxopyridine
medicine
difluorophenyl
imidazolidine
Prior art date
Application number
TW103119743A
Other languages
English (en)
Chinese (zh)
Other versions
TW201536285A (zh
Inventor
亀井準乏
上村大護
住川栄健
徳岡正大
Original Assignee
科研製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 科研製藥股份有限公司 filed Critical 科研製藥股份有限公司
Publication of TW201536285A publication Critical patent/TW201536285A/zh
Application granted granted Critical
Publication of TWI636782B publication Critical patent/TWI636782B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
  • Medicinal Preparation (AREA)
TW103119743A 2013-06-07 2014-06-06 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥 TWI636782B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-120692 2013-06-07
JP2013120692 2013-06-07

Publications (2)

Publication Number Publication Date
TW201536285A TW201536285A (zh) 2015-10-01
TWI636782B true TWI636782B (zh) 2018-10-01

Family

ID=52008252

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103119743A TWI636782B (zh) 2013-06-07 2014-06-06 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥

Country Status (19)

Country Link
US (1) US9518041B2 (es)
EP (1) EP3006437B1 (es)
JP (1) JP6247689B2 (es)
KR (2) KR102379801B1 (es)
CN (1) CN105531270B (es)
AU (1) AU2014275835B2 (es)
BR (1) BR112015030490B1 (es)
CA (1) CA2913858C (es)
ES (1) ES2818931T3 (es)
HK (1) HK1221219A1 (es)
IL (1) IL242861B (es)
MX (1) MX364780B (es)
MY (1) MY173075A (es)
NZ (1) NZ714700A (es)
PH (1) PH12015502661B1 (es)
RU (1) RU2668072C2 (es)
SG (1) SG11201509835RA (es)
TW (1) TWI636782B (es)
WO (1) WO2014196623A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914326A1 (en) * 2013-06-07 2014-12-11 Kaken Pharmaceutical Co., Ltd. Composition for maintaining function of platelets
CN107304205B (zh) * 2016-04-22 2020-10-30 上海医药工业研究院 一种马拉韦罗中间体及其制备方法
EP3517531B1 (en) 2016-09-23 2021-02-24 Kaken Pharmaceutical Co., Ltd. Method for producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301922A1 (en) * 2008-06-17 2011-03-30 Astellas Pharma Inc. Pyridone compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147573A1 (en) * 2001-03-15 2004-07-29 Anders Eriksson Metalloproteinase inhibitors
ATE420068T1 (de) 2001-09-07 2009-01-15 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1546109A4 (en) 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7482370B2 (en) 2004-07-16 2009-01-27 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AR073741A1 (es) 2008-09-24 2010-12-01 Schering Corp Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis
WO2010054278A2 (en) * 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
EP2789607B1 (en) * 2011-12-09 2018-02-07 Kaken Pharmaceutical Co., Ltd. Pyridone derivative and medicine containing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301922A1 (en) * 2008-06-17 2011-03-30 Astellas Pharma Inc. Pyridone compound

Also Published As

Publication number Publication date
BR112015030490B1 (pt) 2022-01-18
CN105531270A (zh) 2016-04-27
AU2014275835B2 (en) 2018-08-16
ES2818931T3 (es) 2021-04-14
EP3006437A4 (en) 2017-03-15
CA2913858A1 (en) 2014-12-11
CA2913858C (en) 2021-07-20
NZ714700A (en) 2020-09-25
MX2015016828A (es) 2016-04-11
JPWO2014196623A1 (ja) 2017-02-23
RU2015156531A (ru) 2017-07-14
EP3006437A1 (en) 2016-04-13
KR20160016834A (ko) 2016-02-15
US9518041B2 (en) 2016-12-13
IL242861B (en) 2018-08-30
RU2668072C2 (ru) 2018-09-27
PH12015502661A1 (en) 2016-03-07
US20160130248A1 (en) 2016-05-12
PH12015502661B1 (en) 2016-03-07
KR20210133326A (ko) 2021-11-05
TW201536285A (zh) 2015-10-01
CN105531270B (zh) 2017-09-05
MY173075A (en) 2019-12-24
EP3006437B1 (en) 2020-08-05
KR102379801B1 (ko) 2022-03-28
HK1221219A1 (zh) 2017-05-26
JP6247689B2 (ja) 2017-12-13
BR112015030490A2 (pt) 2017-07-25
SG11201509835RA (en) 2015-12-30
MX364780B (es) 2019-05-07
KR102321814B1 (ko) 2021-11-05
WO2014196623A1 (ja) 2014-12-11
AU2014275835A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
RU2671847C2 (ru) Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона
CN101490004B (zh) 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烯基醇的衍生物
EP1191931B1 (en) 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
EP1246809B1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
US20200290964A1 (en) Sulfonamide derivatives for protein degradation
TWI636782B (zh) （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥
US20070066651A1 (en) Pyrazoline derivatives useful for the treatment of cancer
US5025024A (en) Therapeutically active fluoro-substituted compound
CN109923101B (zh) 环状化合物
TW202039503A (zh) 苯并噻二嗪衍生物及包含該衍生物之用以治療腺苷媒介疾病的組合物
CN115105503B (zh) 一种trpv1拮抗/cox抑制双靶点药物或其药学上可接受的盐、药物制剂和应用
US9079876B2 (en) Imidazole derivatives and preparation method and use thereof
GB2059963A (en) 2-Amino-3-benzoyl- phenylacetamides and cyclic homologues
ES2214129B1 (es) 3-fenilfuran-2-onas.
CN102086212B (zh) 抗真菌剂-2，3，4，5-四氢-4H-苯并[b]噻喃并[4，3-c]吡唑-2-甲酰胺衍生物
WO2000077003A1 (fr) Composes de pyrrolopyridazine optiquement actifs
CN107311933A (zh) 一类苯并咪唑衍生物，及其制备方法和用途
ES2214130B1 (es) 2-3'-bipiridinas.
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
CN110156704B (zh) 1,2,4-三唑硫醚衍生物及其晶体结构与应用
JP3387066B2 (ja) ピロロピリダジン化合物を含有する抗潰瘍剤
JPH07508508A (ja) アレルギーおよび炎症疾患の治療用化合物